Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Inclusion Criteria

• •Histologically or cytologically documented muscle-invasive UC of the bladder.
• •Participants with transitional cell and mixed transitional/non-transitional cell histologies;
• •Participants with MIBC clinical tumor (T) stage T2-T4aN0/1M0 or UC of the bladder with clinical state T1N1M0 (participants with T1 stage are allowed only with N1 disease)
• •Participants should also have not received prior systemic chemotherapy or immunotherapy for the treatment of MIBC or bladder UC.
• •Medically fit for cystectomy and able to receive neoadjuvant therapy;
• •Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC;
• •ECOG performance status of 0,1,2 at enrollment.
• •Availability of tumor sample prior to study entry;
• •Must have a life expectancy of at least 12 weeks at randomization.
• •Cisplatin-ineligible, following criteria based on Galsky et al 2011 OR Refuse cisplatin based chemotherapy (must be documented in the medical records)